These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36454774)

  • 1. Evaluation of the acute oral toxicity and antipsychotic activity of a dual inhibitor of PDE1B and PDE10A in rat model of schizophrenia.
    Al-Nema M; Gaurav A; Lee MT; Okechukwu P; Nimmanpipug P; Lee VS
    PLoS One; 2022; 17(12):e0278216. PubMed ID: 36454774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
    Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
    Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents.
    Takakuwa M; Watanabe Y; Tanaka K; Ishii T; Kagaya K; Taniguchi H; Kotera J; Hashimoto K
    Pharmacol Biochem Behav; 2019 Oct; 185():172757. PubMed ID: 31404565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor.
    Macek TA; Suzuki K; Asin K; Kimura H
    Int J Neuropsychopharmacol; 2020 Nov; 23(8):524-532. PubMed ID: 32598478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia.
    Świerczek A; Jankowska A; Chłoń-Rzepa G; Pawłowski M; Wyska E
    Curr Drug Targets; 2019; 20(16):1652-1669. PubMed ID: 31368871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents.
    Suzuki K; Harada A; Shiraishi E; Kimura H
    J Pharmacol Exp Ther; 2015 Mar; 352(3):471-9. PubMed ID: 25525190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
    Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
    J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A.
    Redrobe JP; Rasmussen LK; Christoffersen CT; Bundgaard C; Jørgensen M
    Eur J Pharmacol; 2015 Aug; 761():79-85. PubMed ID: 25941078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor MT-3014 in rats.
    Takakuwa M; Watanabe Y; Saijo T; Murata M; Anabuki J; Tezuka T; Sato S; Kojima K; Hashimoto K
    Pharmacol Biochem Behav; 2020 Sep; 196():172972. PubMed ID: 32562717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile.
    Masilamoni GJ; Uthayathas S; Koenig G; Leventhal L; Papa SM
    Neuropharmacology; 2016 Nov; 110(Pt A):449-457. PubMed ID: 27539962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
    Chappie T; Humphrey J; Menniti F; Schmidt C
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
    Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
    Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.
    Bartolomé-Nebreda JM; Delgado F; Martín-Martín ML; Martínez-Viturro CM; Pastor J; Tong HM; Iturrino L; Macdonald GJ; Sanderson W; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
    J Med Chem; 2014 May; 57(10):4196-212. PubMed ID: 24758746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity.
    Vardigan JD; Lange HS; Tye SJ; Fox SV; Smith SM; Uslaner JM
    Psychopharmacology (Berl); 2016 Jul; 233(13):2441-50. PubMed ID: 27117142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological evaluation of a novel phosphodiesterase 10A inhibitor in models of antipsychotic activity and cognition.
    Jones PG; Hewitt MC; Campbell JE; Quinton MS; Engel S; Lew R; Campbell U; Burdi DF
    Pharmacol Biochem Behav; 2015 Aug; 135():46-52. PubMed ID: 25989044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patented PDE10A inhibitors: novel compounds since 2007.
    Kehler J; Kilburn JP
    Expert Opin Ther Pat; 2009 Dec; 19(12):1715-25. PubMed ID: 19939189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine.
    Weber M; Breier M; Ko D; Thangaraj N; Marzan DE; Swerdlow NR
    Psychopharmacology (Berl); 2009 May; 203(4):723-35. PubMed ID: 19066855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of phosphodiesterase (1B, 2A, 9A and 10A) inhibitors on central nervous system cyclic nucleotide levels in rats and mice.
    Chen J; Zook D; Crickard L; Tabatabaei A
    Neurochem Int; 2019 Oct; 129():104471. PubMed ID: 31121256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
    Siuciak JA; Chapin DS; Harms JF; Lebel LA; McCarthy SA; Chambers L; Shrikhande A; Wong S; Menniti FS; Schmidt CJ
    Neuropharmacology; 2006 Aug; 51(2):386-96. PubMed ID: 16780899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms.
    Suzuki K; Harada A; Suzuki H; Miyamoto M; Kimura H
    Neuropsychopharmacology; 2016 Aug; 41(9):2252-62. PubMed ID: 26849714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.